Stock Market & Financial Investment News

News Breaks June 29, 2011 09:11 EDT TSPT Transcept Pharmaceuticals upgraded to Buy from Neutral at Lazard Capital Lazard Capital upgraded Transcept Pharmaceuticals with a $29 price target citing expectations the FDA will approve the company's insomnia treatment Intermezzo on the July 14 PDUFA date. News For TSPT From The Last 14 Days Check below for free stories on TSPT the last two weeks. Sign up for a free trial to see the rest of the stories you've been missing. May 13, 2013 17:12 EDT TSPT Transcept Pharmaceuticals partner to stop using Intermezzo sales reps Subscribe for More Information May 10, 2013 07:25 EDT TSPT Transcept Pharmaceuticals downgraded to Hold from Buy at MLV Equity May 9, 2013 08:00 EDT TSPT Transcept downgraded to Market Perform from Outperform at JMP Securities JMP securities downgraded Transcept following weak script data for Intermezzo. 05:36 EDT TSPT Transcept downgraded to Market Perform from Outperform at Leerink Leerink downgraded Transcept Pharmaceuticals citing weak script data for Intermezzo and lowered its price target range for shares to $4-$5 from $7-$8. May 8, 2013 13:27 EDT TSPT Transcept Pharmaceuticals reports Q1 EPS (56c), consensus (36c) Transcept reported cash, cash equivalents and marketable securities of $81.1M at March 31. Sign up for a free trial to see the rest of the stories you've been missing.